Dr Catherine L. Higgins | Director of Scientific Program Management
Stand Up To Cancer

Dr Catherine L. Higgins, Director of Scientific Program Management, Stand Up To Cancer

Catherine L. Higgins, Ph.D., is Director of Scientific Program Management at Stand Up To Cancer (SU2C), spearheading administration and organization of SU2C's rapidly growing scientific portfolio. Previously, Dr. Higgins was Director of the Human Research Protection Program at Texas A&M University. Within 3 years, she transformed the program to AAHRPP accreditation and decreased average IRB approval times from over 60 days to around 15 days. She was also Adjunct Associate Professor in the Department of Health Policy and Management of the School of Public Health, Texas A&M Health Science Center, teaching courses in foundations of clinical translational research and clinical research methods and design. Formerly, Dr. Higgins was Program Director for the Gulf Coast Consortia which is involved in multi-institutional, interdisciplinary research development in Houston's Texas Medical Center. Her postdoctoral research was in biochemistry of human atherosclerosis at Baylor College of Medicine. She completed her Ph.D. in chemistry specializing in protein folding and biophysical chemistry at Tulane University. She taught chemistry at Jefferson Forest High School in Bedford County, Virginia. She completed her B.S. in chemistry specializing in polymer chemistry along with a music minor at The College of William and Mary in Virginia. Her research has been featured on the covers of journals, such as The FEBS Journal and Arteriosclerosis, Thrombosis, and Vascular Biology. Overall, Dr. Higgins has 20 years’ experience in the research enterprise, ranging from basic sciences and clinical and translational research to research development and compliance, and is interested in fostering innovative scientific research for integration into the community and for benefit to humankind.

Appearances:



West Coast Day 3 @ 2:20

Accelerating progress of precision immunotherapy from laboratory to clinic through strategic collaborations

  • Progress through research, clinical trials and genomic analysis
  • Will these projects lead to us grouping cancers differently, e.g. according to genetic faults?
  • How are we working together to integrate this work and ensure we make therapies available to patients rapidly?
last published: 16/Oct/18 14:45 GMT

back to speakers

Sign Up for Event Updates

Contact us

To sponsor or exhibit contact:
Oliver Breed
+44 (0)207 092 1156

oliver.breed@terrapinn.com


To speak:
Lauren Sheppard
+44 (0)207 092 1211

lauren.sheppard@terrapinn.com